Chiesi Farmaceutici
Chiesi Farmaceutici, a prominent player in the global pharmaceutical industry, is headquartered in Parma, Italy. Founded in 1935, the company has established a strong presence in various operational regions, including Europe, North America, and Asia. Specialising in innovative treatments for respiratory diseases, neonatology, and rare diseases, Chiesi is renowned for its commitment to research and development, which has led to several key milestones in the biopharmaceutical sector. The company’s core products, including advanced inhalation therapies and specialty medicines, are distinguished by their focus on patient-centric solutions. Chiesi Farmaceutici has garnered recognition for its sustainable practices and dedication to improving health outcomes, positioning itself as a leader in the pharmaceutical market. With a rich history and a forward-thinking approach, Chiesi continues to make significant contributions to healthcare worldwide.
DitchCarbon Score
How does Chiesi Farmaceutici's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Chiesi Farmaceutici's score of 63 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Chiesi Farmaceutici's reported carbon emissions
In 2023, Chiesi Farmaceutici reported total greenhouse gas emissions of approximately 980,116,000 kg CO2e globally. This includes Scope 1 emissions of about 29,906,000 kg CO2e, Scope 2 emissions of approximately 591,000 kg CO2e (market-based), and significant Scope 3 emissions of around 955,088,000 kg CO2e, primarily from the use of sold products and purchased goods and services. Chiesi has set ambitious climate commitments, aiming to achieve a 50% reduction in absolute Scope 1 and Scope 2 emissions by 2030, using 2019 as the baseline year. Additionally, the company targets a 90% reduction in absolute Scope 3 emissions from the use of sold products by 2035. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to net-zero emissions across all scopes by 2035. In terms of recent achievements, Chiesi has reported a 12% reduction in Scope 1 emissions and a remarkable 96% reduction in Scope 2 market-based emissions compared to the 2019 baseline, primarily due to increased use of renewable energy sources. Chiesi's climate strategy is comprehensive, focusing on reducing emissions across its entire value chain while maintaining transparency and accountability in its sustainability reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 29,739,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 32,762,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Chiesi Farmaceutici is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
